Total Payments
$3.4M
2024 Payments
$586,458
Companies
18
Transactions
3,220
Medicare Patients
4,154
Medicare Billing
$795,161
Payment Breakdown by Category
Other$1.9M (55.2%)
Consulting$979,222 (28.6%)
Travel$339,149 (9.9%)
Royalty/License$130,000 (3.8%)
Food & Beverage$62,531 (1.8%)
Research$23,475 (0.7%)
Education$42.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 324 | 55.2% |
| Consulting Fee | $979,222 | 171 | 28.6% |
| Travel and Lodging | $339,149 | 1,388 | 9.9% |
| Royalty or License | $130,000 | 4 | 3.8% |
| Food and Beverage | $62,531 | 1,315 | 1.8% |
| Unspecified | $23,475 | 13 | 0.7% |
| Education | $42.25 | 5 | 0.0% |
Payments by Type
General
$3.4M
3,207 transactions
Research
$23,475
2 transactions
Ownership
$0
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $2.0M | 2,337 | $0 (2022) |
| ABBVIE INC. | $1.3M | 740 | $0 (2024) |
| Visant Medical, Inc. | $130,000 | 9 | $0 (2022) |
| MERZ NORTH AMERICA, INC. | $29,859 | 43 | $0 (2024) |
| Galderma Laboratories, L.P. | $20,682 | 54 | $0 (2021) |
| Nordic Pharma, Inc. | $4,999 | 1 | $0 (2024) |
| Merz Pharmaceuticals GmbH | $1,793 | 20 | $0 (2017) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $125.00 | 1 | $0 (2021) |
| Horizon Therapeutics plc | $119.06 | 1 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $108.38 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $586,458 | 321 | ABBVIE INC. ($581,182) |
| 2023 | $644,135 | 410 | ABBVIE INC. ($635,441) |
| 2022 | $652,593 | 527 | Allergan, Inc. ($564,466) |
| 2021 | $569,356 | 637 | Allergan, Inc. ($555,293) |
| 2020 | $202,366 | 237 | Allergan, Inc. ($192,345) |
| 2019 | $364,489 | 603 | Allergan Inc. ($360,233) |
| 2018 | $296,713 | 265 | Allergan Inc. ($179,219) |
| 2017 | $109,322 | 220 | Allergan Inc. ($107,007) |
All Payment Transactions
3,220 individual payment records from CMS Open Payments — Page 1 of 129
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $957.00 | General |
| 12/30/2024 | Nordic Pharma, Inc. | Lacrifill (Device) | Consulting Fee | Cash or cash equivalent | $4,999.02 | General |
| Category: Opthalmics | ||||||
| 12/24/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,196.25 | General |
| 12/24/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,010.17 | General |
| 12/17/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $1,595.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $744.33 | General |
| 12/10/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,153.25 | General |
| 12/10/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $20.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/03/2024 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $31,900.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/03/2024 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $17,500.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/03/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $1,595.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/26/2024 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $17,500.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/26/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,674.75 | General |
| 11/22/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $48.03 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/22/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $40.97 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/22/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $39.56 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/21/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $445.96 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/21/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $336.79 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/21/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $326.84 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/21/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $59.85 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/21/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $58.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/21/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $24.12 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/20/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $89.11 | General |
| 11/20/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/20/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: FACIAL AESTHETICS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Prospective, evaluator-blind, multicenter study to assess the safety and effectiveness of treatment with the Octave System for lifting the eyebrow and improving the appearance of the face and neck | MERZ NORTH AMERICA, INC. | $15,000 | 1 |
| Prospective, evaluator-blind, multicenter study to assess the safety and effectiveness of treatment with the Octave System for lifting the eyebrow and improving the appearance of the face and neck | Merz North America, Inc. | $8,475 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 554 | 567 | $478,689 | $174,344 |
| 2022 | 10 | 857 | 864 | $506,861 | $181,810 |
| 2021 | 12 | 1,362 | 1,386 | $601,287 | $219,592 |
| 2020 | 14 | 1,381 | 3,523 | $626,075 | $219,414 |
Total Patients
4,154
Total Services
6,340
Medicare Billing
$795,161
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92285 | Photography of content of eyes | Office | 2021 | 352 | 355 | $16,330 | $5,590 | 34.2% |
| 67840 | Removal of eyelid growth, other than chalazion (chronic inflammation of the meibomian gland for the eyelid) | Office | 2021 | 11 | 14 | $8,162 | $2,816 | 34.5% |
| 67840 | Removal of eyelid growth, other than chalazion (chronic inflammation of the meibomian gland for the eyelid) | Facility | 2021 | 14 | 16 | $5,646 | $1,074 | 19.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 28 | 28 | $2,688 | $805.25 | 30.0% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 13 | 13 | $2,080 | $414.75 | 19.9% |
| 15823 | Removal of excessive skin and fat of upper eyelid | Facility | 2020 | 189 | 189 | $342,464 | $125,237 | 36.6% |
| 67904 | Repair of tendon of upper eyelid | Facility | 2020 | 38 | 38 | $68,700 | $25,522 | 37.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 280 | 292 | $45,461 | $14,375 | 31.6% |
| 67950 | Enlargement of eyelid margin | Facility | 2020 | 33 | 35 | $37,891 | $10,350 | 27.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 12 | 2,100 | $25,060 | $10,203 | 40.7% |
| 92082 | Measurement of field of vision during daylight conditions | Office | 2020 | 261 | 263 | $25,597 | $8,168 | 31.9% |
| 92285 | Photography of content of eyes | Office | 2020 | 346 | 359 | $16,271 | $5,218 | 32.1% |
| 67840 | Removal of eyelid growth | Office | 2020 | 20 | 27 | $15,461 | $5,195 | 33.6% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 69 | 69 | $15,546 | $4,913 | 31.6% |
| 64612 | Injection of chemical for destruction of nerve muscles on one side of face | Office | 2020 | 14 | 21 | $8,762 | $2,994 | 34.2% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 61 | 69 | $6,570 | $2,382 | 36.3% |
| 67810 | Biopsy of eyelid | Office | 2020 | 12 | 13 | $4,871 | $1,584 | 32.5% |
| 68840 | Probing of nasal-tear duct | Office | 2020 | 14 | 14 | $5,040 | $1,404 | 27.8% |
| 67840 | Removal of eyelid growth | Facility | 2020 | 14 | 16 | $5,515 | $1,027 | 18.6% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 18 | 18 | $2,866 | $842.02 | 29.4% |
About Dr. John Fezza, MD
Dr. John Fezza, MD is a Ophthalmology healthcare provider based in Venice, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184715187.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Fezza, MD has received a total of $3.4M in payments from pharmaceutical and medical device companies, with $586,458 received in 2024. These payments were reported across 3,220 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.9M).
As a Medicare-enrolled provider, Fezza has provided services to 4,154 Medicare beneficiaries, totaling 6,340 services with total Medicare billing of $795,161. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmic Plastic and Reconstructive Surgery
- Location Venice, FL
- Active Since 09/27/2006
- Last Updated 11/27/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1184715187
Products in Payments
- BOTOX (Biological) $1.3M
- BOTOX COSMETIC (Biological) $75,483
- KYBELLA (Biological) $12,173
- Lacrifill (Device) $4,999
- Xeomin (Biological) $3,386
- XEOMIN (Biological) $789.31
- Cequa (Drug) $125.00
- TEPEZZA (Drug) $119.06
- TYRVAYA (Drug) $81.91
- Omidria (Drug) $38.01
- Rhopressa (Drug) $23.72
- Superion Indirect Decompression System (Device) $18.81
- Flarex (Drug) $15.77
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Venice
P Dee Stephenson, M.d., P.a, M.D., P.A
Ophthalmology — Payments: $595,281
Ophthalmology $595,281
Joshua Kim, Md, MD
Ophthalmology — Payments: $282,186
Ophthalmology $282,186
Dr. Priya Mathews, M.d, M.D
Ophthalmology — Payments: $234,923
Ophthalmology $234,923
Dr. Joaquin De Rojas, M.d, M.D
Ophthalmology — Payments: $106,363
Ophthalmology $106,363
Steven Kane, M.d, M.D
Ophthalmology — Payments: $64,773
Ophthalmology $64,773
Dr. David Shoemaker, Md, MD
Ophthalmology — Payments: $8,077
Ophthalmology $8,077